Man, I didn't even try to dail into the CC, but folks are going over it. Even more so than the presentation they had today.
They are saying this is more effective than the top 2 diabetes drugs on the market right now and that lane alone is worth Billions (30).
One Doc said this drug will benefit at least 1/3 of all of the clients he sees.
Mannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn.
Not sure if yall seen it, but I posted a story that said this drug is the same as a company inventing a tree that grew money.
They are saying this is more effective than the top 2 diabetes drugs on the market right now and that lane alone is worth Billions (30).
One Doc said this drug will benefit at least 1/3 of all of the clients he sees.
Mannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn.
Not sure if yall seen it, but I posted a story that said this drug is the same as a company inventing a tree that grew money.
Stock Analysts' HELP PAGE, Stockvadar-offers
($300 scripts (4g) per month x 12 months) x 3M patient USA only population [cited by cardio-doctors study] = $10.8B per year
Going forward 10x , that's $108B Market Cap or ~$360/share give or take.
This doesn't even calculate the rest of the world (ROW).
-sv (STRONG BUY)
($300 scripts (4g) per month x 12 months) x 3M patient USA only population [cited by cardio-doctors study] = $10.8B per year
Going forward 10x , that's $108B Market Cap or ~$360/share give or take.
This doesn't even calculate the rest of the world (ROW).
-sv (STRONG BUY)
Rickdogg44
RIP Charmander RIP Kobe
I might get in on ARMN. I can only get like 100 shares tho
Sunday Night News: Consortium ISSUES $288 PRICE TARGET, Stockvadar-reports
First please comment and thumbs up this post so that all viewers may benefit for our insights going into Monday. And please feel free to copy our comments to your friends however you please in Yahoo's guidelines. We offer this report free of charge to the investment community. We collect no money on viewership. The risk of investing is your own. Thank you.
As all are aware, no one is yet to correctly price target what Vascepa is worth to Amarin let alone a necessary buy-out. We state, 'necessary' because if 83% of 2,500 physicians at the A.H.A. conference are already committed ot prescribing Vascepa, Amarin is simply too small to handle the manufacturing need. We at the consortium have repeatedly argued this issue over the weekend and come back to the same conclusion. Underline this: Given the market potential for Vascepa per year, Amarin must be bought out, and will be bought out, unless they create a massive partnership deal with a mega-pharma capable of ramping production levels to $6B in product per year.
Furthermore, we think Amarin having $1B in product for 2019 is ghastly short of the wave that was created at the A.H.A. this weekend. As one source in the medical community points out, already 3M patients need Vascepa. Now if you follow the comments around pre-diabetics, the potential market need is going to be staggering. This has caused a lot of discussion within the consortium because again and again we think Vascepa scripts are going to rocket ASAP. As one reviewer stated, all those on placebo in the REDUCE-IT trial need to immediately be put on Vascepa--that kind of urgency is undeniable.
To get to a bottom line, we at the consortium are defying the analysts with a price target of $288/share; that's about a $108B market cap based on 375M outstanding shares; we can readjust as necessary. We think this is a unique situation where analysts are extremely hesitant for their own reasons to assign an educated market valuation given the block-buster size of potential Vascepa patients. As we reviewed the A.H.A. presentation and follow-up over and over, it is readily apparent that Vascepa's benefit well-extends beyond trigylcerides to, shall we describe it, 'preventative coronary disease.' Now let's address that.
Irrespective of the FDA (that will have to catch up in one sense), the overwhelming majority of physicians coming out the A.H.A. have openly talked about Vascepa as a medicament for 'preventative coronary disease'--after all, it extends life and limits conditions (e.g. heart attacks) leading ot death. In other words, Vascepa falls into the category of 'preventative medicine' and its general safety tolerance is overwhelmingly excellent as well as affordable. We foresee in advance of most analysts who refuse to cop on or catch up, that Vascepa will be viewed as a medicament, yes, but as a prescriptive-medicament in the vein of a vitamin (though it's not) just as people take Vitamin C, etc. What's the point? The A.H.A. physicians have applauded and accepted Vascepa in spades. This is why Amarin is at the least worth $108B -- we won't trouble you now, but we think that it will be more.
This days ahead for share price are going to be exhilarating for the investor. Our own perspective is that people like the consortium know as we do that Amarin is on the way to triple digit market cap valuation in the billions. Keep in mind, the global opportunity is something the consortium can't even grasp at this point. Again, we state, Amarin must be sold or be taken over in mega-deal perhaps of this new century by a pharma company capable of managing the production need; now this may stun some of our readers; don't be surprised if Amazon enters this game if you understand how they've expanded already--nothing, we repeat, nothing keeps a non-pharmaceutical company like Amazon from jumping all over Amarin. Amazon has the marketing infra-structure, cash, and means to hire and build whatever is needed to make Vascepa a global product bigger than an Apple I-phone. Remember, savvy investors learn to think outside the box. Don't assume that only big pharmas are capable of buying Amarin--only the contrary, even Elon Musk could get in if your mind allows for the potential range of possibilities; that said, we'll leave our conversation there and return to the mundane you all want to read: the stock price target issued by Stockvadar. It is as follows--
$288 PRICE TARGET. Happy investing!!!
-sv (STRONG BUY)
First please comment and thumbs up this post so that all viewers may benefit for our insights going into Monday. And please feel free to copy our comments to your friends however you please in Yahoo's guidelines. We offer this report free of charge to the investment community. We collect no money on viewership. The risk of investing is your own. Thank you.
As all are aware, no one is yet to correctly price target what Vascepa is worth to Amarin let alone a necessary buy-out. We state, 'necessary' because if 83% of 2,500 physicians at the A.H.A. conference are already committed ot prescribing Vascepa, Amarin is simply too small to handle the manufacturing need. We at the consortium have repeatedly argued this issue over the weekend and come back to the same conclusion. Underline this: Given the market potential for Vascepa per year, Amarin must be bought out, and will be bought out, unless they create a massive partnership deal with a mega-pharma capable of ramping production levels to $6B in product per year.
Furthermore, we think Amarin having $1B in product for 2019 is ghastly short of the wave that was created at the A.H.A. this weekend. As one source in the medical community points out, already 3M patients need Vascepa. Now if you follow the comments around pre-diabetics, the potential market need is going to be staggering. This has caused a lot of discussion within the consortium because again and again we think Vascepa scripts are going to rocket ASAP. As one reviewer stated, all those on placebo in the REDUCE-IT trial need to immediately be put on Vascepa--that kind of urgency is undeniable.
To get to a bottom line, we at the consortium are defying the analysts with a price target of $288/share; that's about a $108B market cap based on 375M outstanding shares; we can readjust as necessary. We think this is a unique situation where analysts are extremely hesitant for their own reasons to assign an educated market valuation given the block-buster size of potential Vascepa patients. As we reviewed the A.H.A. presentation and follow-up over and over, it is readily apparent that Vascepa's benefit well-extends beyond trigylcerides to, shall we describe it, 'preventative coronary disease.' Now let's address that.
Irrespective of the FDA (that will have to catch up in one sense), the overwhelming majority of physicians coming out the A.H.A. have openly talked about Vascepa as a medicament for 'preventative coronary disease'--after all, it extends life and limits conditions (e.g. heart attacks) leading ot death. In other words, Vascepa falls into the category of 'preventative medicine' and its general safety tolerance is overwhelmingly excellent as well as affordable. We foresee in advance of most analysts who refuse to cop on or catch up, that Vascepa will be viewed as a medicament, yes, but as a prescriptive-medicament in the vein of a vitamin (though it's not) just as people take Vitamin C, etc. What's the point? The A.H.A. physicians have applauded and accepted Vascepa in spades. This is why Amarin is at the least worth $108B -- we won't trouble you now, but we think that it will be more.
This days ahead for share price are going to be exhilarating for the investor. Our own perspective is that people like the consortium know as we do that Amarin is on the way to triple digit market cap valuation in the billions. Keep in mind, the global opportunity is something the consortium can't even grasp at this point. Again, we state, Amarin must be sold or be taken over in mega-deal perhaps of this new century by a pharma company capable of managing the production need; now this may stun some of our readers; don't be surprised if Amazon enters this game if you understand how they've expanded already--nothing, we repeat, nothing keeps a non-pharmaceutical company like Amazon from jumping all over Amarin. Amazon has the marketing infra-structure, cash, and means to hire and build whatever is needed to make Vascepa a global product bigger than an Apple I-phone. Remember, savvy investors learn to think outside the box. Don't assume that only big pharmas are capable of buying Amarin--only the contrary, even Elon Musk could get in if your mind allows for the potential range of possibilities; that said, we'll leave our conversation there and return to the mundane you all want to read: the stock price target issued by Stockvadar. It is as follows--
$288 PRICE TARGET. Happy investing!!!
-sv (STRONG BUY)
Rickdogg44
RIP Charmander RIP Kobe
I might get in on ARMN. I can only get like 100 shares tho
I got in around $18.50.
Still going down
Rickdogg44
RIP Charmander RIP Kobe
Im debating taking my L on Namaste (NXTTF) and keep it movingI closed my NEPT position and bought ACB
NEPT bullshytted on getting their license far too long. Still a good buy if they ever get it
Im debating taking my L on Namaste (NXTTF) and keep it moving
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Namaste Technologies Inc. To Contact The Firm — PR Newswire
I got in around $18.50.
Still going down
shyt crazy, I added on the dip too, but damn man.
Rickdogg44
RIP Charmander RIP Kobe
funkee
All Star
patience on AMRN, I'm not worried